Zacks: Checkpoint Therapeutics Inc (CKPT) Receives Consensus Rating of “Strong Buy” from Brokerages

Shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price target of $15.50 for the company and are expecting that the company will post ($0.27) EPS for the current quarter, according to Zacks. Zacks has also assigned Checkpoint Therapeutics an industry rank of 193 out of 265 based on the ratings given to related companies.

A number of analysts have recently commented on the company. Zacks Investment Research cut Checkpoint Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. HC Wainwright assumed coverage on Checkpoint Therapeutics in a research report on Friday, December 8th. They issued a “buy” rating and a $11.00 price objective for the company.

Shares of Checkpoint Therapeutics (NASDAQ:CKPT) opened at $4.42 on Monday. Checkpoint Therapeutics has a 12-month low of $3.20 and a 12-month high of $15.00.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.

Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply